Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...

Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. The product ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Me plans to file for bankruptcy and chief executive officer and co-founder Anne Wojcicki will depart, after she repeatedly ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

The issuer is solely responsible for the content of this announcement.

Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories ...

(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...

Refined grains, potatoes and sugary drinks can pack on extra pounds and cause blood sugar to spike, researchers noted. As a ...

If you’re living with heart disease, diabetes, or obesity, moving toward a healthy plant-based diet—rich in whole grains, fruits, vegetables, legumes, and tea or coffee—could help reduce your risk of ...

Every policy decision an elected official makes reflects how they view the purpose of government, Los Angeles Times columnist ...